India's Mankind Pharma rises as Jefferies raises target on growth revival hopes

Mankind Pharma

11/07/2025 05:53

** Shares of Mankind Pharma MNKI.NS rise 4.75% to 2664.4 rupees

** Jefferies reiterates "buy" and hikes price target to 3,000 rupees from 2,870 rupees, implying an upside of 19%

** Jefferies' new price target is the third highest among the 16 analysts covering the stock

** Brokerage sees earnings and growth recovery ahead as Mankind emerges from nine challenging months of core business reorganization and Bharat Serums & Vaccines (BSV) integration

** Expects growth to normalize in the second half of the fiscal 2026 and says valuations remain attractive

** Forecasts fiscal 2027 to be even stronger than FY2026 and estimates 1.5x growth in Indian pharmaceutical market (IPM)

** The average rating of 16 analysts tracking MNKI is "buy"; median PT is 2,730 rupees, according to data compiled by LSEG

** MNKI shares are down 11.7% in 2025 so far, underperforming the 4.7% drop in pharma index .NIPHARM, exchange data shows

 (Reporting by Bharath Rajeswaran in Bengaluru)

 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))